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Abstract
Cholestatic liver injury induced by alpha-naphthylisothiocyanate (ANIT) is provoked by injury to
intrahepatic bile ducts and the progression of hepatic necrosis requires the procoagulant protein
tissue factor (TF) and extrahepatic cells including neutrophils. Recent studies have shown that
myeloid cell TF contributes to neutrophil activation. We tested the hypothesis that myeloid cell TF
contributes to neutrophil activation in ANIT-treated mice. TF activity in liver homogenates
increased significantly in TFflox/flox mice treated with ANIT, but not in TFflox/flox/LysMCre mice
(TFΔMyeloid mice), which have reduced TF expression in monocytes/macrophages and neutrophils.
Myeloid cell-specific TF deficiency did not alter expression of the chemokines KC or MIP-2, but
reduced hepatic neutrophil accumulation in ANIT-treated mice at 48 hours as indicated by tissue
myeloperoxidase (MPO) activity. Myeloid cell TF deficiency significantly reduced CD11b
expression by blood neutrophils in ANIT-treated mice and this was associated with reduced
plasma MPO protein levels, an index of neutrophil degranulation. However, myeloid cell-specific
TF deficiency had no effect on ANIT-induced coagulation cascade activation. The increase in
serum ALT and ALP activities in ANIT-treated mice was reduced by myeloid cell TF deficiency
(p<0.05), but the myeloid cell TF deficiency did not reduce hepatic necrosis at 48 hours, as
determined by histopathology and morphometry. The results suggest that myeloid cell TF
contributes to neutrophil CD11b expression during cholestasis by a coagulation-independent
pathway. However, the resultant reduction in neutrophil accumulation/activation is insufficient to
substantially reduce ANIT hepatotoxicity, suggesting that myeloid cell TF is only one of many
factors modulating hepatic necrosis during cholestasis.
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Introduction
The xenobiotic alpha-naphthylisothiocyanate (ANIT) induces acute cholestatic liver injury
in rodents (Plaa et al., 1976). ANIT-induced bile duct epithelial cell (BDEC) injury releases
high concentrations of bile acids into the hepatic parenchyma. Several studies have indicated
that the progression of hepatic necrosis during acute cholestasis requires inflammatory
mediators. In the case of ANIT-induced liver damage, neutrophils have also been shown to
contribute to hepatocyte injury (Dahm et al., 1991;Kodali et al., 2006). Moreover, we have
shown that tissue factor (TF), a primary activator of blood coagulation, contributes to ANIT-
induced liver damage (Luyendyk et al., 2009). However, the interplay between tissue factor
and neutrophils in cholestatic liver injury has not been explored in detail.
TF is the transmembrane receptor for coagulation factor VIIa and has various roles in
physiology and disease (Mackman, 2004). ANIT-induced hepatocellular necrosis was
reduced in low TF mice (Luyendyk et al., 2009), which express TF at 1% of normal levels
in all cells (Parry et al., 1998). Moreover, ANIT-induced generation of the coagulation
protease thrombin and deposition of fibrin in the liver were TF-dependent (Luyendyk et al.,
2009). However, the mechanism whereby TF contributes to the progression of acute
cholestatic liver injury in this model is not known.
The mechanisms underlying neutrophil-dependent progression of various liver injury
processes including cholestasis have been extensively studied (Jaeschke, 2006). A key
feature of all inflammatory injury models is the activation of circulating neutrophils as
indicated by the increased expression of Mac-1, a heterodimeric integrin comprising CD11b
and CD18, which is needed for extravasation and attack on target cells (Jaeschke, 2006).
The expression of Mac-1 increases in neutrophils after ligation of the common bile duct
(BDL) in mice, and CD18 deficiency reduced necrosis in this model (Gujral et al., 2003).
Similarly, CD18 deficiency reduced necrosis in ANIT-treated mice (Kodali et al., 2006).
Interaction of Mac-1 with ICAM-1 participates in hepatic neutrophil recruitment and
stimulates terminal neutrophil activation and the release of cytotoxic mediators including
reactive oxygen and proteases that damage hepatocytes (Gujral et al., 2004). Of importance,
the mechanisms of CD11b expression by neutrophils during ANIT-induced cholestasis have
not been investigated.
TF has been shown to contribute to neutrophil activation. Neutrophils have been shown
recently to express TF in a form that participates in the oxidative burst, but not in activation
of the coagulation cascade (Redecha et al., 2008). The mechanism whereby TF promoted
neutrophil activation required protease activated receptor-2 (PAR-2), also expressed by
neutrophils (Redecha et al., 2008). Interestingly, another study showed that stimulation of
PAR-2 also increased the expression of CD11b by isolated neutrophils (Howells et al.,
1997). These studies suggest a potential pathway whereby TF could promote the expression
of CD11b by neutrophils. However, this has not been investigated in a model of neutrophil-
dependent hepatotoxicity.
In the present study, we used a genetic approach to determine the role of TF expressed by
myeloid cells in ANIT-induced neutrophil activation, coagulation and hepatic injury.
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Male mice between the ages of 8-16 weeks were used for these studies. Generation of the
TFflox/flox mice has been described previously (Pawlinski et al., 2007). Crossing the
TFflox/flox mice with mice expressing the Cre recombinase under control of the M Lysozyme
(LysM) promoter selectively reduces TF expression in myeloid cells (neutrophils and
macrophages) by >90% (Redecha et al., 2007;Pawlinski et al., 2010). Littermate TFflox/flox/
LysMCre mice (hereafter referred to as TFΔMyeloid mice) and TFflox/flox mice (hereafter
referred to as control mice) on an identical genetic background (N6 C57Bl/6J) were used for
experiments. These mice were generated by breeding male TFΔMyeloid mice with female
control mice. Mice were maintained in an AAALAC-accredited facility at the University of
Kansas Medical Center. Mice were housed at an ambient temperature of 22°C with
alternating 12-h light/dark cycles, and allowed water and rodent chow ad libitum (Teklad
8604; Harlan, Indianapolis, IN). All animal procedures were performed according to the
guidelines of the American Association for Laboratory Animal Science and were approved
by the KUMC Institutional Animal Care and Use Committee.
ANIT hepatotoxicity model
Mice fasted overnight were treated with a single dose of alpha-naphthylisothiocyanate
(ANIT) (Sigma-Aldrich, St. Louis, MO) dissolved in corn oil (60 mg/kg, p.o.) or corn oil
alone (control [vehicle] treatment) at 10 ml/kg. Food was removed at 6 pm and returned
after treatment with ANIT or vehicle between 8-9 am. The mice were anesthetized using
isoflurane 24 or 48 hours after ANIT treatment for the collection of blood and liver samples.
Blood was collected from the caudal vena cava into a syringe containing sodium citrate
(final concentration, 0.38%) and additional blood was collected into a syringe without
anticoagulant. Plasma and serum were collected from this blood by centrifugation. Sections
of liver from the left lateral lobe were fixed in 10% neutral-buffered formalin. The right
medial lobe was cut into a cube and affixed to a cork using OCT and frozen for 3 minutes in
liquid nitrogen-chilled isopentane. The remaining liver was snap frozen in liquid nitrogen.
Tissue myeloperoxidase (MPO) activity and plasma MPO levels
Neutrophil accumulation in the liver was estimated by measuring liver homogenate MPO
activity. 100 mg of frozen liver was homogenized in a buffer containing 0.5% hexadecyl
trimethyl ammonium bromide, 10 mM EDTA and 50 mM Na2PO4, pH 5.4 and subjected to
3 freeze-thaw cycles followed by centrifugation at 12,000 × g for 15 minutes at 4°C. MPO
activity in the supernatant was determined by addition of 50 mM Na2PO4 containing 0.167
mg/ml o-dianisidine dihydrochloride (Sigma) and 0.0005% hydrogen peroxide (Sigma) in
50 mM phosphate buffer (pH 6.0). MPO activity was expressed as the change in absorbance
measured at 460 nm per mg of protein in the liver homogenate. Plasma MPO protein levels
were determined using a commercial ELISA (Cell Sciences, Canton, MA).
Clinical chemistry and chemokine measurement
The serum activities of alanine aminotransferase (ALT) and alkaline phosphatase (ALP)
were determined using commercially available reagents (Thermo Scientific). Levels of KC
and MIP-2 protein in the plasma were determined using commercial ELISAs (R&D
Systems, Minneapolis, MN).
Evaluation of liver tissue factor activity, thrombin generation, and liver fibrin deposition
Coagulation cascade activation terminates in generation of the protease thrombin.
Antithrombin in the plasma binds rapidly to thrombin, inhibiting its activity. The thrombin-
antithrombin complex (TAT) is relatively stable in plasma and is extensively utilized as an
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indicator of thrombin generation/coagulation cascade activation. TAT levels in plasma were
determined using a commercial ELISA kit (Siemens Healthcare Diagnostics, Deerfield, IL).
Procoagulant (TF) activity of liver homogenates was performed as described previously
(Ganey et al., 2007) using a single-stage clotting assay. In brief, 100 mg of snap-frozen liver
was homogenized in HEPES/saline containing 15 mM N-octyl-D-glucopyranoside. 50 μL of
this homogenate was added to an equal amount of citrated mouse plasma (Equitech Bio,
Carroll, TX) and 25mM CaCl2 added to activate the coagulation cascade. The time to clot
formation was evaluated using a STart4 coagulation analyzer (Diagnostica Stago) and
compared to a standard curve generated using mouse-brain extract (a source of mouse tissue
factor). The TF-dependent procoagulant activity of each sample was identified by repeating
each assay in the presence of an inhibitory rat anti-mouse TF antibody (100 μg/ml, 1H1),
kindly provided by Dr. Daniel Kirchhofer (Genentech). Hepatic fibrin in liver extracts was
detected by Western blotting using the mouse anti-human fibrin antibody (59D8, kindly
provided by Dr. Charles Esmon, Oklahoma Medical Research Foundation) as described
previously (Luyendyk et al., 2009). This antibody detects fibrin at an epitope revealed
specifically by thrombin cleavage of fibrinogen (Weiler-Guettler et al., 1998).
RNA isolation, cDNA synthesis, and real-time PCR
RNA was isolated from approximately 100 mg of snap-frozen liver using TRI reagent
(Molecular Research Center, Inc., Cincinnati, OH). cDNA synthesis was performed using 1
microgram of RNA and a High Capacity cDNA Reverse Transcription kit (Applied
Biosystems) and MyCycler thermal cycler (Bio-Rad). Levels of ICAM-1 and GAPDH
mRNA were determined using TaqMan gene expression assays and TaqMan gene
expression master mix (Applied Biosystems) on an ABI Prism 7300 sequence detection
system (Applied Biosystems). The expression of ICAM-1 mRNA was normalized relative to
GAPDH expression levels, and relative expression level determined using the comparative
Ct method.
Cytokeratin-19 staining and quantification
5 micron frozen sections obtained from livers frozen in isopentane/OCT were used. For
cytokeratin 19 (CK19) staining, sections were fixed in 4% neutral-buffered formalin and
then blocked with 10% goat serum in PBS for 1 hour at room temperature. The sections
were then washed with PBS and incubated with the monoclonal rat anti-mouse CK19
antibody (1:1000 in block buffer, clone, TROMA-3). The TROMA-3 antibody developed by
R. Kemler (Brulet et al., 1980) was obtained from the Developmental Studies Hybridoma
Bank developed under the auspices of the NICHD and maintained by The University of
Iowa, Department of Biology, Iowa City, IA. The sections were incubated with anti-rat
Alexa-conjugated secondary antibody (Invitrogen), washed with PBS, counterstained with
DAPI, and coverslipped. The area of positive CK-19 staining was determined in 5 randomly
selected 100X magnification images utilizing Scion Image Software.
Histopathology
Formalin-fixed livers (48 hours post-dosing) were subjected to routine processing, sectioned
at 5 microns, stained with hematoxylin and eosin, and evaluated by light microscopy. At
least two sections of liver were evaluated from each animal. Sections were approximately 1
to 1.5 cm long and 0.3 to 0.5 cm wide (at the widest part). Each section was evaluated in its
entirety. The severity of necrosis was also assigned a score by a pathologist (G.H.C) in a
masked fashion, using a scale of 0 to 5, as we have described previously (Luyendyk et al.,
2009). In addition, morphometry was performed. The slides were scanned using a
ScanscopeXT (Aperio, Vista CA), foci of necrosis (i.e., bile infarcts) were identified and
circled manually, and the area of necrosis determined by Spectrum Imagescope software
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(Aperio, Vista CA). The percent of necrosis was determined by dividing the sum of the
necrotic areas by the total area of the sections.
Flow cytometry
Neutrophil CD11b expression by cells expressing high levels of Gr-1, a marker of mature
granulocytes (Hestdal et al., 1991;Fleming et al., 1993) was assessed as described
previously (Williams et al., 2010). Briefly, whole blood containing heparin as anticoagulant
was collected and immediately placed on ice. 0.5 μg of Cy5-labeled-anti-Gr-1 (BioLegend,
San Diego, CA) and PE-labeled-anti-CD11b (BioLegend) diluted in 0.1% BSA/PBS were
added to 50 μL whole blood. Tubes were incubated for 30 minutes on ice in the dark. After
washing with 0.1% BSA, red blood cells were lysed using RBC lysing solution (0.155 M
NH4Cl, 10 mM KHCO3, 0.1 mM EDTA). Pelleted cells were washed three times with 0.1%
BSA then fixed with 2.5% buffered formalin. Samples were analyzed on the FACSCalibur
(BD, Franklin Lakes, NJ).
Statistics
Comparison of two groups was performed using Student's t-test. Comparison of 3 or more
groups was performed using one-way analysis of variance and Student-Newman-Keul's
post-hoc test. Datasets resistant to transformation to achieve a normal distribution were
compared utilizing the Mann-Whitney Rank Sum Test. The criterion for statistical
significance was P≤0.05.
Results
Effect of myeloid cell-specific TF deficiency on liver procoagulant activity and coagulation
cascade activation in ANIT-treated mice
In agreement with our previous studies (Luyendyk et al., 2009), liver procoagulant (TF)
activity increased 48 hours after ANIT treatment in control mice (TFflox/flox mice) (Fig. 1A).
This increase was reduced by approximately 50% in TFΔMyeloid mice treated with ANIT
(Fig. 1A). This result is consistent with the hypothesis that myeloid cells expressing TF
accumulate in livers of ANIT-treated mice. Unlike our previous finding that ANIT-induced
thrombin generation is reduced by >75% in low TF mice (Luyendyk et al., 2009), plasma
thrombin-antithrombin (TAT) levels were not significantly affected by myeloid cell TF
deficiency in ANIT-treated mice at 24 or 48 hours (Fig. 1B). Similarly, hepatic fibrin
deposition in livers at 48 hours was not significantly affected by myeloid cell TF deficiency
(Fig. 1C).
Effect of myeloid cell-specific TF deficiency on neutrophil CD11b expression in ANIT-
treated mice
Mature neutrophils in the blood express high levels of Gr-1 (Hestdal et al., 1991;Fleming et
al., 1993) and during cholestasis these cells are stimulated to express increased levels of
CD11b (Gujral et al., 2003). CD11b expression on circulating neutrophils reflects CD11b
expression on liver accumulated neutrophils (Williams et al., 2010). To determine whether
myeloid cell TF contributed to Gr-1 or CD11b expression on circulating neutrophils, we
utilized flow cytometry. ANIT treatment increased the percentage of Gr-1-high cells (i.e.,
mature granulocytes) in the blood, and this was significantly reduced in TFΔMyeloid mice
(Fig. 2A). Neutrophil CD11b expression and the percentage of Gr-1-high/CD11b-high cells
increased in ANIT-treated mice, and this was significantly reduced by myeloid cell TF
deficiency (Fig. 2B-C). These results suggest that myeloid cell TF deficiency impairs
neutrophil CD11b priming in ANIT-treated mice. In agreement with this result, plasma
MPO levels, an index of neutrophil degranulation (Stegenga et al., 2008;Su et al., 2005;van
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Leeuwen et al., 2008), were reduced in ANIT-treated TFΔMyeloid mice compared to ANIT-
treated control mice (Fig. 2D).
Effect of myeloid cell-specific TF deficiency on liver myeloperoxidase activity, chemokine
and ICAM-1 expression in ANIT-treated mice
The accumulation of neutrophils in the liver was determined by measuring the activity of
myeloperoxidase (MPO) in tissue homogenates. Tissue MPO activity increased to a similar
extent in both ANIT-treated control mice and ANIT-treated TFΔMyeloid mice at 24 hours
(Fig. 3A). In contrast, tissue MPO activity was significantly decreased in ANIT-treated
TFΔMyeloid mice at 48 hours (Fig. 3A). Myeloid cell TF deficiency did not impact the
increase in plasma levels of the neutrophil chemokines KC and MIP-2 (Fig. 3B-C) or
induction of ICAM-1 mRNA in liver (Fig. 3D). The data indicate that reducing myeloid cell
TF expression reduces hepatic neutrophil accumulation without impacting ICAM-1 or
chemokine expression.
Effect of myeloid cell-specific TF deficiency on ANIT-induced liver injury
Early ANIT-induced biliary injury is elicited by an ANIT-GSH conjugate transported into
the bile by canalicular MRP2 in hepatocytes (Dietrich et al., 2001;Carpenter-Deyo et al.,
1991). Of importance, myeloid cell TF deficiency did not affect basal MRP2 mRNA
expression in liver (data not shown). Serum ALT and ALP activities increased in ANIT-
treated control mice at 24 hours and increased further at 48 hours. The increase in these
biomarkers of injury was attenuated in ANIT-treated TFΔMyeloid mice (Fig. 4A-B). Despite
this reduction in ALT, there was no reduction in necrosis in ANIT-treated TFΔMyeloid mice
(Fig. 4C), as determined by histopathologic examination and assignment of a necrosis
severity score as we have described previously (Luyendyk et al., 2009). This conclusion is
supported by morphometric examination, which did not identify a statistically significant
difference in the area of necrosis between groups at 48 hours (Fig. 4D). Biliary hyperplasia,
as indicated by an increase in cytokeratin-19 (CK-19) staining, was not affected by myeloid
cell TF deficiency (Fig. 4E, Supplemental Fig. 1).
Discussion
It is increasingly clear that TF can contribute to disease by mechanisms independent of
coagulation cascade activation (Versteeg et al., 2006). An important example of this
contribution is a series of experiments indicating that TF expressed by neutrophils
contributes to the oxidative burst within these cells (Redecha et al., 2007). In light of our
previous studies showing that TF deficiency in all cells reduces ANIT-induced liver injury,
we tested the hypothesis that myeloid cell TF contributed to neutrophil activation and
hepatotoxicity in ANIT-treated mice. Overall, the results suggest that TF contributes to
CD11b upregulation by neutrophils in ANIT-treated mice, but that this effect is insufficient
to significantly affect ANIT-induced liver necrosis 48 hours after ANIT administration.
However, we cannot exclude the possibility that myeloid cell TF-deficiency impacts ANIT-
induced liver injury at later time points (e.g., 72 hours) during the early phase of liver repair
(Ohta et al., 1999).
TF can exist in a form that participates in cell signaling, but does not activate blood
coagulation (Ahamed et al., 2006). For example, in a model of anti-phospholipid antibody-
induced pregnancy loss, the amplication of neutrophil activation by TF was not inhibited by
the monoclonal antibody 5G9, which selectively inhibits procoagulant TF (Redecha et al.,
2008). Interestingly, liver procoagulant activity was reduced in ANIT-treated TFΔMyeloid
mice, suggesting a contribution of myeloid cells to hepatic TF antigen levels during
cholestatic liver injury. However, myeloid cell TF deficiency did not affect coagulation
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cascade activation in ANIT-treated mice. This discrepancy may be due to the assay utilized
to measure liver TF activity. We utilized an assay of liver TF procoagulant involving the
detergent, N-octyl-glucopyranoside, which converts cryptic non-procoagulant TF to a
procoagulant form detected by the assay (Versteeg et al., 2007). Accordingly, the level of
TF activity in liver homogenate does not necessarily reflect the ability of myeloid cell TF to
elicit coagulation cascade activation in vivo.
In contrast to myeloid cell-specific TF deficiency, global TF-deficiency reduced coagulation
and liver necrosis in ANIT-treated mice. This indicates that TF expression by another cell
type is essential for thrombin generation, and that thrombin likely participates in ANIT
hepatotoxicity. Indeed, we found that both hepatic fibrin and the thrombin receptor PAR-4
contribute to ANIT-induced liver injury in mice (Luyendyk et al., 2010). Candidate cell
types expressing TF required for thrombin generation in this model include BDECs and
hepatocytes, both of which are damaged during the progression of ANIT-induced liver
injury, and have been shown to express TF (Stephenne et al., 2007;Luyendyk et al., 2009).
TF staining colocalized with the BDEC marker cytokeratin-19 in the livers of ANIT-treated
mice suggests exposure of BDEC-derived TF to the sinusoidal blood near areas of necrosis
(Luyendyk et al., 2009). However, additional studies are required to determine the cell type
expressing TF required for ANIT-induced coagulation.
Neutrophils are key players in the progression of cell injury in various models of liver
disease, including cholestatic liver injury (Gujral et al., 2003;Kodali et al., 2006). Sequential
activation of neutrophils during cholestasis involves upregulation of adhesion molecules
including Mac-1 (CD11b/CD18) on circulating neutrophils, accumulation in the liver, which
likely involves to some extent the chemokines MIP-2 and KC (Xu et al., 2004), and
transmigration across the sinusoidal endothelium. The engagement of Mac-1 with ICAM-1
expressed by hepatocytes triggers terminal activation resulting in neutrophil degranulation
and formation of a long-lasting oxidant stress in close proximity to hepatocytes (Gujral et
al., 2003;Gujral et al., 2004). Interestingly, we found that myeloid cell TF deficiency
significantly reduced neutrophil priming in the blood, evidenced by reduced cell surface
expression of CD11b. Indeed, systemic activation of neutrophils, as indicated by increased
CD11b expression, is observed in other models where neutrophils contribute to liver injury,
including hepatic ischemia-reperfusion (Jaeschke et al., 1993) and obstructive cholestasis
(Gujral et al., 2003). In ANIT-treated mice, the increased CD11b expression occurred with
the increase in plasma MPO activity, which is a marker of neutrophil degranulation
(Stegenga et al., 2008;Su et al., 2005;van Leeuwen et al., 2008). The fact that TF deficiency
reduced CD11b expression and plasma MPO levels suggests that TF contributes to the
upregulation of adhesion molecules on neutrophils and promotes neutrophil cytotoxicity
during cholestasis. In another model, a similar activation of neutrophils by TF was
identified, and determined to involve the TF cytoplasmic domain and PAR-2 (Redecha et
al., 2008). Indeed, stimulation of PAR-2 on neutrophils increases surface expression of
CD11b (Howells et al., 1997). Taken together, the results support the hypothesis that TF
contributes to neutrophil activation during cholestasis.
ANIT-induced liver necrosis was reduced in low TF mice, which have TF levels reduced to
near 1% of normal in all cells (Luyendyk et al., 2009). Although the reduction in CD11b
expression by neutrophils in ANIT-treated TFΔMyeloid mice was associated with a significant
reduction in serum ALT and ALP activities, our study did not identify a significant effect on
necrosis in ANIT-treated TFΔMyeloid mice. The lack of effect on myeloid cell TF deficiency
on necrosis could also relate to the incomplete inhibition of neutrophil activation in these
mice. Indeed, the presence of a threshold for neutrophil-dependent hepatotoxicity is evident
in several models of liver injury, including ANIT-induced cholestasis. For example, in liver
ischemia-reperfusion, reducing the number of circulating neutrophils by 65% did not affect
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liver injury, whereas a reduction of approximately 90% significantly reduced necrosis
(Jaeschke et al., 1990). In a model of endotoxin/D-galactosamine-induced liver injury,
extravasation of approximately 30% of accumulated neutrophils is sufficient to produce
maximal hepatotoxicity (Essani et al., 1995). With respect to the ANIT model, hepatic
neutrophil accumulation is reduced by 50% in CXCR2-/- mice, but hepatocellular injury is
unaffected (Xu et al., 2004). Similarly, whereas a complete loss of CD18 reduced ANIT-
induced necrosis in mice, a 70% reduction in CD18 levels was insufficient to affect the
progression of ANIT-induced liver injury in mice (Kodali et al., 2006). Myeloid cell TF
deficiency did not completely prevent CD11b upregulation on circulating neutrophils, nor
did it abolish the increase in plasma MPO, suggesting that substantial neutrophil activation
still occurs in ANIT-treated TFΔMyeloid mice. Overall, it is likely that myeloid cell TF is one
of many factors contributing to neutrophil activation and hepatotoxicity in this model.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Effect of myeloid cell specific TF deficiency on liver TF activity and coagulation
cascade activation in ANIT-treated mice
TFflox/flox/LysMCre mice (TFΔMyeloid mice) and TFflox/flox mice (control mice) were treated
with vehicle or ANIT (60 mg/kg, po). (A) Liver TF activity was determined 48 hours later
as described (see Methods). n=5-9 mice per group. (B) Plasma thrombin-antithrombin levels
were determined 24 and 48 hours later. n=5-12 mice per group. TAT levels in vehicle-
treated mice did not differ between 24 and 48 h. Data from 48 h are shown. (C)
Representative western blot showing hepatic fibrin in liver determined as described in
Methods. Quantification (n=5-6 mice per group) by densitometry is shown below. Data are
expressed as mean ± SEM. *Significantly different from vehicle-treated control mice of the
same genotype. #Significantly different from ANIT-treated control mice at that time.
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Figure 2. Effect of myeloid cell specific TF deficiency on neutrophil CD11b expression and
plasma MPO protein levels in ANIT-treated mice
TFflox/flox/LysMCre mice (TFΔMyeloid mice) and TFflox/flox mice (control mice) were treated
with vehicle or ANIT (60 mg/kg, po). For A-C, flow cytometric analysis was performed as
described in Methods to determine the (A) % Gr-1-high cells (Gr-1 bright), (B) CD11b
staining intensity of Gr-1-positive cells, and (C) % Gr-1-high/CD11b-high (% Gr-1 bright/
CD11b bright) cells in blood. (D) Plasma MPO protein levels were determined by ELISA.
n=4-7 mice per group. Levels of each biomarker in vehicle-treated mice did not differ
between 24 and 48 h. Data from 48 h are shown. Data are expressed as mean ± SEM.
*Significantly different from vehicle-treated control mice of the same
genotype. #Significantly different from ANIT-treated control mice at that time.
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Figure 3. Effect of myeloid cell specific TF deficiency on liver myeloperoxidase activity, and
chemokine and ICAM-1 expression in ANIT-treated mice
TFflox/flox/LysMCre mice (TFΔMyeloid mice) and TFflox/flox mice (control mice) were treated
with vehicle or ANIT (60 mg/kg, po) and liver and plasma collected 24 or 48 hours later.
(A) Liver homogenate MPO activity was determined as an indicator of neutrophil
accumulation. Plasma (B) MIP-2 and (C) KC protein levels were determined by ELISA and
(D) hepatic ICAM-1 mRNA levels determined using real-time PCR. n=5-12 mice per group.
Levels of each biomarker in vehicle-treated mice did not differ between 24 and 48 h. Data
from 48 h are shown. Data are expressed as mean ± SEM. *Significantly different from
vehicle-treated control mice of the same genotype. #Significantly different from ANIT-
treated control mice at that time.
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Figure 4. Effect of myeloid cell specific TF deficiency on ANIT-induced liver injury
TFflox/flox/LysMCre mice (TFΔMyeloid mice) and TFflox/flox mice (control mice) were treated
with vehicle or ANIT (60 mg/kg, po) and liver and plasma collected 24 or 48 hours later.
Serum (A) ALT activity and (B) ALP activity were determined at 24 and 48 hours. The
severity of liver necrosis was (C) assigned a severity score by a pathologist and (D)
morphometric determination of the percentage of necrotic liver tissue was performed as
described in Methods. (E) The area of liver occupied by the biliary marker cytokeratin-19
(CK-19) was determined as described in Methods. Data are expressed as mean ± SEM.
n=10-14 mice per group for A-D and 3 mice per group for E. *Significantly different from
vehicle-treated control mice of the same genotype. #Significantly different from ANIT-
treated control mice at that time.
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